BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liaw YF. Finite nucleos(t)ide analog therapy in HBeAg-negative chronic hepatitis B: an emerging paradigm shift. Hepatol Int. 2019;13:665-673. [PMID: 31559604 DOI: 10.1007/s12072-019-09989-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 Peng CW, Jeng WJ. The main reasons for finite Nuc therapy in HBeAg-negative chronic hepatitis B patients. Hepatol Int 2021;15:527-8. [PMID: 33904110 DOI: 10.1007/s12072-021-10168-9] [Reference Citation Analysis]
2 Jeng WJ, Liaw YF. Finite Antiviral Therapy in Chronic Hepatitis B Patients with Cirrhosis. Semin Liver Dis 2021;41:349-57. [PMID: 34182587 DOI: 10.1055/s-0041-1729973] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Lai CY, Yang SS, Lee SW, Tsai HJ, Lee TY. Cessation of Nucleos(t)ide Analogue Therapy in Non-Cirrhotic Hepatitis B Patients with Prior Severe Acute Exacerbation. J Clin Med 2021;10:4883. [PMID: 34768403 DOI: 10.3390/jcm10214883] [Reference Citation Analysis]
4 Liaw YF, Jeng WJ. Benefit of stopping finite nucleos(t)ide analogues therapy in chronic hepatitis B patients. Gut 2020;69:1898-9. [PMID: 31784470 DOI: 10.1136/gutjnl-2019-320341] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Kaewdech A, Assawasuwannakit S, Sripongpun P, Chamroonkul N, Tangkijvanich P, Piratvisuth T. Clinical Utility of SCALE-B to Predict Hepatitis B Virus Relapse, Hepatitis B Surface Antigen Loss After Antiviral Cessation in Asian Patients After 2-Year Follow-up. Front Med 2022;9:859430. [DOI: 10.3389/fmed.2022.859430] [Reference Citation Analysis]
6 Medas R, Liberal R, Macedo G. Discontinuation of antiviral therapy in chronic hepatitis B patients. World J Clin Cases 2021; 9(24): 6979-6986 [PMID: 34540953 DOI: 10.12998/wjcc.v9.i24.6979] [Reference Citation Analysis]
7 Jeng WJ, Liu YC, Peng CW, Chien RN, Liaw YF. Highly significant differences in HBsAg kinetics among patients with two types of hepatitis B flare, with and without retreatment. J Antimicrob Chemother 2021:dkab360. [PMID: 34618028 DOI: 10.1093/jac/dkab360] [Reference Citation Analysis]
8 Manolakopoulos S, Kranidioti H, Kourikou A, Deutsch MM, Triantos C, Tsolias C, Manesis EK, Mathou N, Alexopoulou A, Hadziyannis E, Papatheodoridis G. Long-term clinical outcome of HBeAg-negative chronic hepatitis B patients who discontinued nucleos(t)ide analogues. Liver Int 2021;41:48-57. [PMID: 33373114 DOI: 10.1111/liv.14654] [Reference Citation Analysis]
9 Pierra Rouviere C, Dousson CB, Tavis JE. HBV replication inhibitors. Antiviral Res 2020;179:104815. [PMID: 32380149 DOI: 10.1016/j.antiviral.2020.104815] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
10 Liaw YF, Chien RN. Finite nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B: From an "option" to an "active recommendation". Kaohsiung J Med Sci 2022. [PMID: 35262284 DOI: 10.1002/kjm2.12518] [Reference Citation Analysis]
11 Shih C, Wu SY, Chou SF, Yuan TT. Virion Secretion of Hepatitis B Virus Naturally Occurring Core Antigen Variants. Cells 2020;10:E43. [PMID: 33396864 DOI: 10.3390/cells10010043] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Boyd A, Dezanet LNC, Lacombe K. Functional Cure of Hepatitis B Virus Infection in Individuals With HIV-Coinfection: A Literature Review. Viruses 2021;13:1341. [PMID: 34372547 DOI: 10.3390/v13071341] [Reference Citation Analysis]
13 Kao JH, Jeng WJ, Ning Q, Su TH, Tseng TC, Ueno Y, Yuen MF. APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients. Hepatol Int 2021;15:833-51. [PMID: 34297329 DOI: 10.1007/s12072-021-10223-5] [Reference Citation Analysis]
14 Liaw YF. Stopping Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B. Gastroenterology 2020;159:1186. [PMID: 32433984 DOI: 10.1053/j.gastro.2020.01.056] [Reference Citation Analysis]
15 Jeng WJ, Chien RN, Liaw YF. Disputing issues in the paradigm change to finite antiviral therapy in HBeAg negative patients. J Hepatol 2021:S0168-8278(21)01847-X. [PMID: 34214616 DOI: 10.1016/j.jhep.2021.06.027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Zuccaro V, Asperges E, Colaneri M, Marvulli LN, Bruno R. HBV and HDV: New Treatments on the Horizon. J Clin Med 2021;10:4054. [PMID: 34575165 DOI: 10.3390/jcm10184054] [Reference Citation Analysis]
17 Liaw YF. Undesirable Long-Term Outcome of Entecavir Therapy in Chronic Hepatitis B With Cirrhosis. Clin Gastroenterol Hepatol 2020;18:2146-7. [PMID: 32088301 DOI: 10.1016/j.cgh.2020.02.028] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Liaw YF. Hepatitis B Flare After Cessation of Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B: To Retreat or Not to Retreat. Hepatology 2021;73:843-52. [PMID: 32810321 DOI: 10.1002/hep.31525] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 13.0] [Reference Citation Analysis]
19 Su TH, Kao JH. Withdrawal of Nucleos(t)ide Analogues in Hepatitis B e Antigen-Negative Patients: An Asian Perspective. Clin Liver Dis (Hoboken) 2020;16:244-8. [PMID: 33489096 DOI: 10.1002/cld.950] [Reference Citation Analysis]
20 Chien RN, Liaw YF. Current Trend in Antiviral Therapy for Chronic Hepatitis B. Viruses 2022;14:434. [PMID: 35216027 DOI: 10.3390/v14020434] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
21 Hu Z, Hu J, Ren F, Xu H, Tan M, Wang Q, Ren J. Nobiletin, a novel inhibitor, inhibits HBsAg production and hepatitis B virus replication. Biochem Biophys Res Commun 2020;523:802-8. [PMID: 31954513 DOI: 10.1016/j.bbrc.2019.12.099] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
22 Kaewdech A, Sripongpun P. Challenges in the discontinuation of chronic hepatitis B antiviral agents. World J Hepatol 2021; 13(9): 1042-1057 [PMID: 34630873 DOI: 10.4254/wjh.v13.i9.1042] [Reference Citation Analysis]
23 Hadziyannis E, Hadziyannis S. Current practice and contrasting views on discontinuation of nucleos(t)ide analog therapy in chronic hepatitis B. Expert Rev Gastroenterol Hepatol 2020;14:243-51. [PMID: 32162562 DOI: 10.1080/17474124.2020.1738219] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Huang PY, Wang JH, Hung CH, Lu SN, Hu TH, Chen CH. The role of hepatitis B virus core-related antigen in predicting hepatitis B virus relapse after cessation of entecavir in hepatitis B e antigen-negative patients. J Viral Hepat 2021;28:1141-9. [PMID: 33932245 DOI: 10.1111/jvh.13528] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]